Saban allowed to keep 24% of Keshet

November 1, 2005 02:50
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


New Bezeq owner Haim Saban will be allowed to keep a 24 percent share in broadcasting company Keshet, after the the Knesset Economics committee gave its approval to amend the law obligating him to lower his stake to 5%. Saban recently bought a controlling stake in Bezeq which, because of its ownership of satellite TV company Yes, he was required to divest in Keshet, a franchisee of Channel 2. Saban currently owns a 27.8% stake in Keshet and by the cable and satellite law could only keep 5% if he took ownership of Bezeq and, with it, Yes. By a different law, the second broadcasting authority law, Saban could keep 24% of Keshet for the Bezeq deal to go through. Communications Minister Dalia Itzik recommended that the two laws become consistent at 24%, which the Economics committee agreed to in Mondays session.

More about:Dalia Itzik, Knesset

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings